These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

709 related articles for article (PubMed ID: 27281199)

  • 21. Mechanisms of PD-1/PD-L1 expression and prognostic relevance in non-Hodgkin lymphoma: a summary of immunohistochemical studies.
    Gravelle P; Burroni B; Péricart S; Rossi C; Bezombes C; Tosolini M; Damotte D; Brousset P; Fournié JJ; Laurent C
    Oncotarget; 2017 Jul; 8(27):44960-44975. PubMed ID: 28402953
    [TBL] [Abstract][Full Text] [Related]  

  • 22.
    Godfrey J; Tumuluru S; Bao R; Leukam M; Venkataraman G; Phillip J; Fitzpatrick C; McElherne J; MacNabb BW; Orlowski R; Smith SM; Kline J
    Blood; 2019 May; 133(21):2279-2290. PubMed ID: 30910787
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PD-1 and PD-L1 Up-regulation Promotes T-cell Apoptosis in Gastric Adenocarcinoma.
    Chiu YM; Tsai CL; Kao JT; Hsieh CT; Shieh DC; Lee YJ; Tsay GJ; Cheng KS; Wu YY
    Anticancer Res; 2018 Apr; 38(4):2069-2078. PubMed ID: 29599324
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A frequent somatic mutation in CD274 3'-UTR leads to protein over-expression in gastric cancer by disrupting miR-570 binding.
    Wang W; Sun J; Li F; Li R; Gu Y; Liu C; Yang P; Zhu M; Chen L; Tian W; Zhou H; Mao Y; Zhang L; Jiang J; Wu C; Hua D; Chen W; Lu B; Ju J; Zhang X
    Hum Mutat; 2012 Mar; 33(3):480-4. PubMed ID: 22190470
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Potential biomarker for checkpoint blockade immunotherapy and treatment strategy.
    Dong ZY; Wu SP; Liao RQ; Huang SM; Wu YL
    Tumour Biol; 2016 Apr; 37(4):4251-61. PubMed ID: 26779629
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Frequent genetic alterations in immune checkpoint-related genes in intravascular large B-cell lymphoma.
    Shimada K; Yoshida K; Suzuki Y; Iriyama C; Inoue Y; Sanada M; Kataoka K; Yuge M; Takagi Y; Kusumoto S; Masaki Y; Ito T; Inagaki Y; Okamoto A; Kuwatsuka Y; Nakatochi M; Shimada S; Miyoshi H; Shiraishi Y; Chiba K; Tanaka H; Miyano S; Shiozawa Y; Nannya Y; Okabe A; Kohno K; Atsuta Y; Ohshima K; Nakamura S; Ogawa S; Tomita A; Kiyoi H
    Blood; 2021 Mar; 137(11):1491-1502. PubMed ID: 33512416
    [TBL] [Abstract][Full Text] [Related]  

  • 27. DDX3 regulates cancer immune surveillance via 3' UTR-mediated cell-surface expression of PD-L1.
    Chen HH; Yu HI; Chang JJ; Li CW; Yang MH; Hung MC; Tarn WY
    Cell Rep; 2024 Mar; 43(3):113937. PubMed ID: 38489268
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cdk5 disruption attenuates tumor PD-L1 expression and promotes antitumor immunity.
    Dorand RD; Nthale J; Myers JT; Barkauskas DS; Avril S; Chirieleison SM; Pareek TK; Abbott DW; Stearns DS; Letterio JJ; Huang AY; Petrosiute A
    Science; 2016 Jul; 353(6297):399-403. PubMed ID: 27463676
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PD-1 Blockade Boosts Radiofrequency Ablation-Elicited Adaptive Immune Responses against Tumor.
    Shi L; Chen L; Wu C; Zhu Y; Xu B; Zheng X; Sun M; Wen W; Dai X; Yang M; Lv Q; Lu B; Jiang J
    Clin Cancer Res; 2016 Mar; 22(5):1173-1184. PubMed ID: 26933175
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Epigenetic regulators of programmed death-ligand 1 expression in human cancers.
    Kumar S; Sharawat SK
    Transl Res; 2018 Dec; 202():129-145. PubMed ID: 30401465
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Programmed cell death ligand 1 (PD-L1) expression is not a predominant feature in Ewing sarcomas.
    Spurny C; Kailayangiri S; Jamitzky S; Altvater B; Wardelmann E; Dirksen U; Hardes J; Hartmann W; Rossig C
    Pediatr Blood Cancer; 2018 Jan; 65(1):. PubMed ID: 28868758
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Determinants of gastric cancer immune escape identified from non-coding immune-landscape quantitative trait loci.
    Miliotis C; Ma Y; Katopodi XL; Karagkouni D; Kanata E; Mattioli K; Kalavros N; Pita-Juárez YH; Batalini F; Ramnarine VR; Nanda S; Slack FJ; Vlachos IS
    Nat Commun; 2024 May; 15(1):4319. PubMed ID: 38773080
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Regulation of PD-L1 expression in a high-grade invasive human oral squamous cell carcinoma microenvironment.
    Hirai M; Kitahara H; Kobayashi Y; Kato K; Bou-Gharios G; Nakamura H; Kawashiri S
    Int J Oncol; 2017 Jan; 50(1):41-48. PubMed ID: 27922697
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Implications of TCGA Network Data on 2nd Generation Immunotherapy Concepts Based on PD-L1 and PD-1 Target Structures].
    Peters I; Tezval H; Kramer MW; Wolters M; Grünwald V; Kuczyk MA; Serth J
    Aktuelle Urol; 2015 Nov; 46(6):481-5. PubMed ID: 26560846
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Programmed death-1 (PD-1), programmed death-ligand 1 (PD-L1), and EBV-encoded RNA (EBER) expression in Hodgkin lymphoma.
    Paydas S; Bağır E; Seydaoglu G; Ercolak V; Ergin M
    Ann Hematol; 2015 Sep; 94(9):1545-52. PubMed ID: 26004934
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting programmed cell death ligand 1 by CRISPR/Cas9 in osteosarcoma cells.
    Liao Y; Chen L; Feng Y; Shen J; Gao Y; Cote G; Choy E; Harmon D; Mankin H; Hornicek F; Duan Z
    Oncotarget; 2017 May; 8(18):30276-30287. PubMed ID: 28415820
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Programmed death ligand 1 is expressed by non-hodgkin lymphomas and inhibits the activity of tumor-associated T cells.
    Andorsky DJ; Yamada RE; Said J; Pinkus GS; Betting DJ; Timmerman JM
    Clin Cancer Res; 2011 Jul; 17(13):4232-44. PubMed ID: 21540239
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma.
    Darb-Esfahani S; Kunze CA; Kulbe H; Sehouli J; Wienert S; Lindner J; Budczies J; Bockmayr M; Dietel M; Denkert C; Braicu I; Jöhrens K
    Oncotarget; 2016 Jan; 7(2):1486-99. PubMed ID: 26625204
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The prognostic significance of PD-L1 in bladder cancer.
    Huang Y; Zhang SD; McCrudden C; Chan KW; Lin Y; Kwok HF
    Oncol Rep; 2015 Jun; 33(6):3075-84. PubMed ID: 25963805
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Protein Expression of Programmed Death 1 Ligand 1 and HER2 in Gastric Carcinoma.
    Oki E; Okano S; Saeki H; Umemoto Y; Teraishi K; Nakaji Y; Ando K; Zaitsu Y; Yamashita N; Sugiyama M; Nakashima Y; Ohgaki K; Oda Y; Maehara Y
    Oncology; 2017; 93(6):387-394. PubMed ID: 28910818
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 36.